Tenet Healthcare
THC
$263.19
-0.15%
Tenet Healthcare is a Dallas-based healthcare services organization operating 50 acute and specialty hospitals and hundreds of ambulatory surgery centers and outpatient facilities concentrated in the U.S. South, alongside its Conifer revenue cycle management segment. The company has evolved from a highly leveraged hospital operator into a more focused, outpatient-weighted care delivery platform, with its USPI ambulatory surgery franchise now the strategic centerpiece and margin engine. The current investor narrative centers on the Q3 2026 earnings beat and raised full-year EPS guidance, the durability of hospital segment strength, and an expanding capital-return program funded by robust free cash flow and aggressive share repurchases. Debate now hinges on whether the ambulatory expansion runway and buyback-driven EPS compounding can sustain the re-rating after a year of dramatic multiple expansion, particularly as peers consolidate and payer mix remains a swing factor.…
THC
Tenet Healthcare
$263.19
Related headlines
Investment Opinion: Should I buy THC Today?
Rating: Buy (accumulate on weakness). The core thesis is that Tenet is a cash-compounding, deleveraging-adjacent care platform whose $3.328 billion TTM free cash flow and shrinking share count (87.3 million to 80.1 million over the year) mechanically drive per-share earnings growth faster than the underlying business, and the Street's 19 Buys versus zero Sells with a $308.91 average target (about 8.0% upside) endorses that trajectory. The Q3 2026 beat-and-raise — revenue up 18.68% year-over-year to $6.277 billion and net income of $1.0 billion versus $342 million a year earlier — confirms the operating engine is intact.
Supporting evidence is broad: net margin expanded sequentially from 13.08% in Q1 to 14.68% in Q2 to 15.93% in Q3; EBITDA margin reached 31.85% on $1.999 billion of EBITDA; ROE is 33.34% and ROA 8.68%; and the stock trades at 12.73x trailing and 14.10x forward earnings, 0.84x sales, and 6.29x EV/EBITDA — inexpensive on cash flow for a business with an 82.26% gross margin. Buybacks of $255 million in Q3, $1.042 billion in Q2, and $318 million in Q1 were funded entirely from internal cash, and the $27.10 consensus forward EPS against a $286.03 price leaves valuation support even after the 45.44% one-year run.
Three risks could invalidate the thesis: leverage (3.12x debt-to-equity, 70.87% debt-to-capital, roughly $203 million quarterly interest expense), payer-mix volatility (the Q1 2026 revenue miss on unfavorable insurance mix), and multiple compression from 12.73x near the top of its recent 4.7x–13.9x band. The rating would upgrade to a stronger Buy if the stock pulls back toward the $265 analyst low target while margins hold above 15%, and would downgrade to Hold if hospital-segment volume or payer mix deteriorates enough to force a guidance cut, or if the forward PE inversion (14.10x forward versus 12.73x trailing) proves to be genuine earnings normalization rather than a one-time-item artifact. Verdict: fairly valued to modestly undervalued relative to consensus and cheap on EV/EBITDA, but no longer statistically cheap on its own PE history — a Buy for investors comfortable with 1.201 beta and 34.08% historical drawdowns, not a deep-value entry.
Sign up to view all
THC 12-Month Price Forecast
The forward view is constructive but tempered: Tenet's operating momentum (18.68% revenue growth, 15.93% Q3 net margin, $1.999 billion EBITDA) and cash generation support the consensus $308.91 target, while the 12.73x trailing PE near the top of its recent band and only 8.0% implied upside cap the near-term reward. The 14.10x forward PE exceeding the trailing multiple is the key ambiguity — if it reflects one-time items in the trailing figure, the stock is cheaper than it looks; if it reflects genuine earnings normalization, the re-rating is largely done. I would upgrade to high confidence on a pullback toward the $265 analyst low target with margins intact, or on evidence that hospital payer mix has stabilized; I would downgrade to neutral if the next quarter shows margin compression below 15% or a guidance cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Tenet Healthcare's 12-month outlook, with a consensus price target around $308.91 and implied upside of +17.4% versus the current price.
Average Target
$308.91
23 analysts
Implied Upside
+17.4%
vs. current price
Analyst Count
23
covering this stock
Price Range
$265 - $342
Analyst target range
Coverage is deep and overwhelmingly bullish: 22 analysts rate the stock, with 19 Buys, 4 Holds, and zero Sells, producing a consensus recommendation of "buy" and a recommendation mean of 1.57 (where 1.0 is a strong buy). The average target price of $308.91 implies roughly 8.0% upside from the current $286.03, a modest but positive signal that suggests the stock is fairly valued to slightly undervalued relative to where the Street sees it heading. The consensus leans clearly bullish, consistent with the post-Q3 beat-and-raise momentum and the string of reiterated Overweight/Buy/Outperform ratings from Barclays, KeyBanc, Truist, Leerink, Wells Fargo, RBC, and Guggenheim through late October and early November.
The target range of $265.00 to $342.00 is moderately wide — a spread of about 29% from low to high — signaling meaningful dispersion in assumptions. The high target of $342.00 (roughly 19.6% above the current price) likely assumes continued ambulatory expansion, sustained hospital volume growth, further buyback accretion, and multiple expansion toward the upper end of historical ranges; the low target of $265.00 (about 7.3% below current) likely prices in payer mix deterioration, margin compression from labor costs, or a leverage-driven de-rating. Notably, the low target sits above the 52-week low of $157.58, suggesting analysts see limited downside from here, and the absence of any Sell ratings combined with repeated reiterations rather than downgrades points to strong conviction — though the clustering of target revisions around the November 2–4 earnings window means the Street is still digesting the latest guidance raise.
Bulls vs Bears: THC Investment Factors
The bull case currently holds the stronger evidence: 18.68% revenue growth, net margin expansion from 13.08% to 15.93% across 2026, $3.328 billion of TTM free cash flow, and a shrinking share count from 87.3 million to 80.1 million together form a coherent compounding story that the Street endorses with 19 Buys and zero Sells. The bear case rests less on fundamentals than on price and structure — 12.73x trailing PE near the top of its two-year range, only 8.0% upside to the $308.91 average target, 3.12x debt-to-equity, and a demonstrated payer-mix sensitivity from the Q1 revenue miss. The single most important tension is whether buyback-driven EPS compounding and ambulatory expansion can sustain the re-rating now that the multiple has already expanded, or whether the forward PE exceeding the trailing PE correctly anticipates earnings normalization. How the next two quarters resolve the payer-mix and hospital-volume question — not the ambulatory story, which is well understood — will most change the thesis.
Bullish
- Q3 beat with raised EPS guidance: Q3 2026 revenue of $6.277 billion grew 18.68% year-over-year versus $5.289 billion in Q3 2025, and net income jumped to $1.0 billion from $342 million. Management raised the full-year 2026 EPS outlook on the October 29 print, and the stock gapped to $292.25 on November 4, confirming the market rewarded the beat-and-raise.
- Buyback-driven EPS compounding: Share count fell from 87.3 million to 80.1 million over the year, with $255 million of buybacks in Q3, $1.042 billion in Q2, and $318 million in Q1 — all funded from internal cash. With TTM free cash flow of $3.328 billion against a $17.9 billion market cap, the repurchase runway remains substantial and mechanically amplifies per-share growth.
- Margin expansion is real and sequential: Net margin climbed from 13.08% in Q1 to 14.68% in Q2 to 15.93% in Q3, while operating income of $1.75 billion produced a 27.88% operating margin and EBITDA margin reached 31.85%. The improvement reflects volume leverage, payer mix recovery from the soft Q1, and cost discipline rather than one-time items.
- Cheap on cash flow and EV/EBITDA: At 12.73x trailing and 14.10x forward earnings, 0.84x sales, and 6.29x EV/EBITDA, Tenet screens inexpensive for a business generating 33.34% ROE and an 82.26% gross margin. The forward EPS estimate of $27.10 against a $286.03 price leaves room for multiple support even after the 45.44% one-year run.
Bearish
- Leverage remains the structural constraint: Debt-to-equity of 3.12x and total-debt-to-capitalization of 70.87% reflect an acquisition-driven, capital-intensive model, and interest expense runs about $203 million per quarter. Interest coverage of 8.62x is adequate but leaves limited cushion if EBITDA compresses, and the leverage is precisely why equity multiples sit below less-levered peers.
- Valuation near top of recent range: The 12.73x trailing PE sits near the top of the roughly 4.7x–13.9x band of the past two years, and the stock trades at 89.3% of its 52-week range after a 45.44% one-year gain. The forward PE of 14.10x exceeding the trailing 12.73x implies the market expects earnings to normalize lower from the current quarterly run-rate.
- Payer mix is a demonstrated swing factor: Q1 2026 revenue fell short on unfavorable patient insurance mix, showing how quickly volume-driven growth can wobble on reimbursement dynamics. With hospital operations contributing $4.26 billion of Q3 revenue versus $1.371 billion from ambulatory, the legacy inpatient base still carries most of the exposure to mix and labor cost pressure.
- Momentum is decelerating: The stock is up only 5.31% over the past month and 6.77% over three months versus 45.44% over one year, indicating consolidation after the July–August surge from roughly $199 to $280. A 34.08% maximum drawdown over the period and a beta of 1.201 mean corrections in this name are sharp, and the post-earnings fade from $292.25 to $286.03 shows profit-taking pressure near the $301.44 high.
THC Technical Analysis
Tenet is in a powerful, sustained uptrend, with the stock up 45.44% over the past year and 43.41% year-to-date, dramatically outpacing the S&P 500's 12.27% and 10.62% respective gains. At $286.03, the stock sits at roughly 89.3% of its 52-week range of $157.58 to $301.44, positioning it near the upper end of its band — a sign of persistent momentum rather than a value entry point, though it also raises the risk of overextension given the stock is still about 5.1% below its 52-week high. The 34.08% maximum drawdown over the period underscores that this has been a volatile climb rather than a smooth one.
Short-term momentum is positive but decelerating relative to the longer-term move: the stock is up 5.31% over the past month and 6.77% over three months, well below the 45.44% one-year gain, indicating consolidation after the July–August surge from roughly $199 to $280. Relative strength remains decisively positive, with 1-month relative strength of 7.57 and 3-month of 9.60 against a declining SPY (-2.26% and -2.83% respectively), meaning Tenet is outperforming even as the market pulls back. The November 4 gap higher to $292.25 on the Q3 beat and raised guidance marked a fresh momentum thrust, though the stock has since eased to $286.03, suggesting some post-earnings profit-taking rather than a trend reversal.
Key resistance sits at the 52-week high of $301.44, and a clean breakout above that level would confirm the uptrend's continuation and likely invite momentum-driven flows; support is anchored at the 52-week low of $157.58, with intermediate support likely in the $250–$260 zone where the stock consolidated through September and October. With a beta of 1.201, Tenet is roughly 20% more volatile than the market, meaning position sizing should account for amplified drawdowns — the 34.08% max drawdown is a reminder that this name can correct sharply even within a structural uptrend, and a short ratio of 2.62 indicates moderate short interest that could fuel squeezes on strength.
Beta
1.20
1.20x market volatility
Max Drawdown
-34.1%
Largest decline past year
52-Week Range
$158-$301
Price range past year
Annual Return
+41.0%
Cumulative gain past year
| Period | THC Return | S&P 500 |
|---|---|---|
| 1m | -2.2% | -9.7% |
| 3m | -6.3% | -9.9% |
| 6m | +51.5% | -7.5% |
| 1y | +41.0% | +4.7% |
| ytd | +32.0% | +1.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
THC Fundamental Analysis
Revenue is accelerating impressively: Q3 2026 revenue of $6.277 billion grew 18.68% year-over-year versus $5.289 billion in Q3 2025, and the sequential trajectory from $5.368 billion in Q1 to $5.628 billion in Q2 to $6.277 billion in Q3 shows clear acceleration rather than deceleration. Segment data shows Hospital Operations contributing $4.26 billion and Ambulatory Care $1.371 billion, with the ambulatory franchise the strategic growth driver as Tenet continues shifting its mix toward higher-margin outpatient care. The Q1 2026 revenue softness tied to unfavorable patient insurance mix appears to have been fully overcome, and the raised 2026 EPS outlook signals management confidence in the durability of this growth trajectory.
Profitability is robust and improving: Q3 2026 net income reached $1.0 billion with a net margin of 15.93%, up sharply from $342 million and a 6.47% net margin in Q3 2025, while operating income of $1.75 billion produced a 27.88% operating margin. The reported gross margin of 62.5% in Q3 (versus a noisy 18.19% in Q2 and 16.43% in Q1 due to segment cost classification inconsistencies) and the 82.26% gross margin in the key metrics data reflect a high-margin care delivery model, and EBITDA of $1.999 billion (31.85% EBITDA margin) confirms strong cash generation at the operating level. The margin expansion story is real — net margin has climbed from 13.08% in Q1 to 14.68% in Q2 to 15.93% in Q3 — driven by volume leverage, payer mix improvement, and cost discipline.
Balance sheet leverage remains the key risk: debt-to-equity of 3.12x and a total-debt-to-capitalization ratio of 70.87% reflect the capital-intensive, acquisition-driven nature of the hospital business, though interest coverage of 8.62x and a current ratio of 1.76 provide adequate cushion. Free cash flow is strong at $3.328 billion TTM, with Q3 2026 FCF of $1.083 billion on operating cash flow of $1.281 billion and capex of just $198 million, and ROE of 33.34% and ROA of 8.68% demonstrate efficient capital deployment. Management is aggressively returning capital — $255 million of buybacks in Q3, $1.042 billion in Q2, and $318 million in Q1 — funded entirely from internal cash generation, which is shrinking the share count (from 87.3 million to 80.1 million over the year) and amplifying per-share growth.
Quarterly Revenue
$6.3B
2026-09
Revenue YoY Growth
+18.7%
YoY Comparison
Gross Margin
62.5%
Latest Quarter
Free Cash Flow
$3.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is THC Overvalued?
Because Tenet is solidly profitable (Q3 2026 net income of $1.0 billion), the PE ratio is the appropriate primary metric: the stock trades at 12.73x trailing earnings and 14.10x forward earnings, an unusual configuration where the forward multiple exceeds the trailing multiple. This inversion implies the market expects earnings to normalize lower from the current elevated quarterly run-rate, or that the trailing figure is inflated by one-time items — a dynamic worth monitoring, though the consensus forward EPS estimate of $27.10 against a $286.03 price still frames the stock as inexpensive on an absolute basis.
Relative to the broader healthcare sector, Tenet's 12.73x trailing PE and 0.84x PS ratio look cheap, but the comparison is complicated by the company's 3.12x debt-to-equity leverage, which depresses equity multiples relative to less-levered peers. On EV/EBITDA of 6.29x, Tenet screens as a reasonably valued leveraged care provider, and its 82.26% gross margin and 16.14% operating margin are competitive for the medical care facilities industry. The 4.25x price-to-book ratio reflects the market's willingness to pay above book for a business generating 33.34% ROE, suggesting the discount on earnings multiples is a leverage artifact rather than a quality discount.
Historically, Tenet's PE has ranged from as low as 1.21x (Q1 2024, distorted by a one-time gain) to 37.54x (Q2 2022), with the more recent band settling between roughly 4.7x and 13.9x over the past two years; the current 12.73x sits near the top of that recent range, indicating the market is pricing in optimistic expectations after the stock's 45% run. The PS ratio of 0.84x, however, is near the low end of its historical range (which has spanned roughly 1.0x to 3.4x), a divergence that reflects the massive revenue base growth and margin expansion rather than deterioration. Net-net, the stock is not statistically cheap on its own history, but the earnings growth and buyback-driven share count reduction provide a credible path to multiple support.
PE
12.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 1x~17x
vs. Industry Avg
18.9x
Industry PE ~18.9x*
EV/EBITDA
6.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on leverage and earnings quality. Debt-to-equity of 3.12x with total debt at 70.87% of capitalization and roughly $203 million of quarterly interest expense means a meaningful share of operating cash flow is pre-committed, and interest coverage of 8.62x would thin quickly in an EBITDA downturn. The forward PE of 14.10x exceeding the trailing 12.73x implies the market expects earnings to normalize below the Q3 run-rate, so any shortfall in the raised 2026 EPS guidance would hit a stock priced for delivery. Revenue is also concentrated: hospital operations generated $4.26 billion of Q3's $6.277 billion versus $1.371 billion from ambulatory, leaving the majority of the top line exposed to inpatient volume, labor costs, and payer mix — the same mix issue that caused the Q1 2026 revenue shortfall.
Market and competitive risks are dominated by valuation compression and sector dynamics. After a 45.44% one-year and 43.41% YTD gain, the stock trades at 89.3% of its 52-week range and near the top of its recent 4.7x–13.9x PE band, so multiple normalization alone could erase a year of relative outperformance; the beta of 1.201 amplifies any broad market drawdown. The Surgery Partners take-private by HealthSpan at $5.7 billion signals accelerating consolidation in ambulatory surgery, which could raise acquisition multiples for the outpatient assets that underpin Tenet's growth narrative or invite competitive scale from better-capitalized rivals. Regulatory and reimbursement pressure on Medicare and commercial payer rates remains a persistent overhang for the hospital segment, and the 2.62 short ratio means positioning is not so washed out that a squeeze would cushion a fundamental disappointment.
A worst-case scenario would combine payer-mix deterioration in the hospital segment, an EBITDA miss that pushes leverage metrics toward covenant-sensitive territory, and multiple compression from 12.73x toward the low end of its recent range. The 52-week low of $157.58 represents roughly a 45% decline from the current $286.03, and the 34.08% maximum drawdown over the past year shows that a move of that magnitude is not hypothetical for this name. The analyst low target of $265.00 implies a more contained 7.3% downside, but that assumes the beat-and-raise holds; a genuine guidance cut could plausibly take the stock toward the $250–$260 consolidation zone and, in a severe case, back toward the low $200s — a loss of 10% to 30% from current levels, with the full 45% drawdown to $157.58 as the tail scenario.
FAQ
Ranked by severity, the first risk is financial leverage: debt-to-equity of 3.12x, total debt at 70.87% of capitalization, and roughly $203 million of quarterly interest expense mean interest coverage of 8.62x thins quickly if EBITDA of $1.999 billion slips. Second is payer-mix and reimbursement volatility — the Q1 2026 revenue shortfall on unfavorable patient insurance mix shows how fast volume-driven growth can wobble, and hospital operations still supply $4.26 billion of the $6.277 billion quarterly top line. Third is valuation compression: after a 45.44% one-year gain the stock trades near the top of its recent PE band, and with a beta of 1.201 a broad market drawdown is amplified — the 34.08% maximum drawdown over the past year is the evidence. Fourth is competitive consolidation, with Surgery Partners' $5.7 billion HealthSpan take-private potentially raising acquisition multiples for the ambulatory assets that anchor the growth story.
The scenario-weighted forecast is constructive: a 55% base case targets $295–$315 (anchored on the $308.91 analyst average, about 8.0% upside) assuming full-year 2026 EPS near the $27.10 consensus and net margin holding at or above 15%. A 25% bull case reaches $330–$342 (up to 19.6% upside) on ambulatory expansion, further buybacks, and a breakout above the $301.44 52-week high toward the $342 analyst high target. A 20% bear case falls to $240–$265 on payer-mix deterioration, an EBITDA miss, and multiple compression toward the low end of the recent range, approaching the $265 analyst low target. The base case is most likely because the beat-and-raise quarter, the $3.328 billion free cash flow, and the 19-Buy/zero-Sell consensus all point to delivery rather than disappointment; the key assumption is that hospital payer mix has stabilized.
The answer depends on the metric: THC looks cheap on cash flow and sales but no longer cheap on its own earnings history. At 6.29x EV/EBITDA, 0.84x sales, and 5.06x price-to-cash-flow, the market is pricing a leveraged hospital operator rather than a high-quality compounder, and the 4.25x price-to-book reflects a business earning 33.34% ROE. However, the 12.73x trailing PE sits near the top of the roughly 4.7x–13.9x band of the past two years, and the unusual 14.10x forward PE exceeding the trailing multiple implies the market expects earnings to normalize below the Q3 run-rate. The 0.84x PS ratio is near the low end of its historical 1.0x–3.4x range, a divergence explained by revenue-base growth and margin expansion rather than deterioration. Net-net the stock is fairly valued to modestly undervalued versus the $308.91 consensus and cheap on EV/EBITDA, but the market is no longer paying a discount on earnings — it is paying for delivery on the raised 2026 guidance.
From a risk/reward standpoint the setup is moderately favorable rather than compelling: the $308.91 average analyst target implies about 8.0% upside, while the $265 low target implies roughly 7.3% downside, so the skew is positive but thin. The fundamental engine is strong — 18.68% revenue growth, net margin expanding from 13.08% in Q1 to 15.93% in Q3, $3.328 billion of TTM free cash flow, and a share count down from 87.3 million to 80.1 million — and 19 of 22 analysts rate it Buy with zero Sells. The biggest downside risk is a repeat of the Q1 2026 payer-mix shortfall combined with multiple compression from 12.73x, which could take the stock toward the $250–$260 zone. It is a good buy for patient investors accumulating on weakness toward the $265 analyst low target with margins intact, and a less attractive entry at $286.03 after a 45.44% one-year gain.
THC is better suited to a medium-to-long holding period of at least 12 to 24 months than to short-term trading. The growth stage is mature-but-transitioning — a 99,000-employee operator of 50 hospitals shifting toward higher-margin ambulatory surgery — so earnings visibility is decent but not bond-like, and the 1.201 beta plus a 34.08% maximum drawdown means short-term price action is dominated by quarterly prints and payer-mix headlines rather than by the compounding thesis. There is no dividend (0% payout ratio, zero yield), so total return depends entirely on EPS growth, buyback accretion, and multiple stability, which favors patience over trading. The buyback program — $255 million in Q3, $1.042 billion in Q2, $318 million in Q1 — mechanically compounds per-share value over multi-year horizons. A concrete minimum holding period of 12 months aligns with the base-case target window and allows time for the ambulatory expansion and share-count reduction to work through earnings.

